Novartis
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2012, the Group achieved net sales of USD 56.7 billion, while R&D throughout the Group amounted to approximately USD 9.3 billion (USD 9.1 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 129,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at twitter.com/novartis.
POSTED
02-28-13
University of Cape Town and Novartis Collaboration Helps African-based Scientists Tackle African Diseases, Starting with Tuberculosis and Malaria
The University of Cape Town (UCT) and the Novartis Institutes for BioMedical Research (NIBR) are working together to bridge the gap between basic science and clinical research to advance innovative medicines that treat African patients.
The collaboration with the University’s Drug Discove...
POSTED
02-28-13
Novartis Collaboration Aims to Eliminate Rheumatic Heart Disease (RHD) in Zambia, Africa
- RHD has been eliminated in most developed nations, but sub-Saharan Africa studies show at least 2-3% of school-age children suffer from this often fatal disease1
- Collaboration between Novartis physicians, Zambian healt...
POSTED
01-17-13
Novartis makes progress in the fight to eliminate leprosy worldwide
Novartis celebrates the one-year anniversary of an unprecedented, coordinated effort to eliminate or control 10 neglected tropical diseases (NTDs) by 2020. The commitment was captured in the landmark London Declaration on NTDs in which Novartis and a group of partners, including the World Health ...
POSTED
12-04-12
Novartis Foundation Symposium Discusses Psychosocial Support To Help Vulnerable Children Achieve Mental Health And Wellbeing For A Better Future In Sub-Saharan Africa
- Symposium speakers assess psychosocial approaches and discuss various interventions to ensure mental health and wellbeing for Africa's children
- Experts present findings from REPSSI, the Regional Psychosocial Support Initiative ...
POSTED
08-29-12
Novartis International BioCamp Highlights Global R&D Reach to Meet Patient Needs in Emerging Markets
Novartis International BioCamp Highlights Global R&D Reach to Meet Patient Needs in Emerging Markets
- International event brings 60 university students from 21 countries and territories to Novartis headquarters in Basel, Switzerland
POSTED
04-26-12
More Than 25,000 Novartis Associates Worldwide to Volunteer for Local Causes in Community Partnership Day
- Novartis associates worldwide to dedicate 200,000 work hours to supporting the local community
- Highest associate participation to date; activities now benefiting hundreds of charities in 54 countries
- Annual volunteer event...
POSTED
03-28-12
Novartis Launches the Cancer Cell Line Encyclopedia (CCLE) to Catalogue World's Cancer Cell Lines
- Collaboration with the Broad Institute yields comprehensive encyclopedia of genetic and molecular information for nearly 1,000 cancer cell lines
- Encyclopedia, publicly available, may improve the design of cancer trials and advance cance...
POSTED
02-22-12
Delivery Of Child-Friendly Antimalarial Hits The 100 Million Mark
One hundred million treatments of Coartem®Dispersible (artemether-lumefantrine), an antimalarial developed especially for children with P. falciparum malaria, have been delivered by Novartis to 39 malaria-endemic countries, Medicines for Malaria Venture (MMV) announce...
POSTED
01-30-12
Novartis Extends Commitment to Help Achieve Final Elimination of Leprosy
- New five-year commitment includes donation of treatments worth an estimated USD 22.5 million and is expected to reach an estimated 850,000 patients
- Novartis will also intensify efforts to build a multi-stakeholder initiative in a final push against leprosy
POSTED
12-02-11
Novartis Foundation symposium looks at impact of Information and Communication Technology on democratization and development
- Experts analyze how e-health applications improve access to quality healthcare and help contribute to achieving the health-related Millennium Development Goals
- The symposium discusses the role of social media platforms in the Arab Spring and the impact of mobil...
